Solubility Enhancement of Lamotrigine by Liquisolid Technique

Introduction:The term ‘liquisolid system’ describes a pharmaceutical formulation approach where a liquid drug is transformed into a dry, powdered form. Aim: The study’s goal was to utilize LS technology to convert Lamotrigine (LTG) into a more soluble and bioavailable form, which could have significant implications for the treatment of conditions that require this medication, such as epilepsy and bipolar disorder. FTIR analyses were used to determine the drug and excipients’ compatibility. Materials and Methods: Following preliminary screening, Transcutol was selected as the nonvolatile solvent and Avicel pH 102 and MCC as carrier materials in formulation of LS tablets. The coating substance chosen was Aerosil 200. Prior to pounding the liquid-solid powder into tablets, a precompression study was conducted. The pills’ physical and chemical properties as well as results of dissolution tests were examined. The pharmacopoeial tolerances were met by all formulations. A comparison of the dissolution rates of LTG and conventional tablet demonstrates that the formulation of liquisolid tablets is beneficial and useful in contrast to regular traditional tablets. Results: Transcutol and Prosolv SMCC 50 were chosen as the optimized components in the LS formulation. These choices led to a significant enhancement in the dissolution rate of LTG, addressing its low water solubility, and potentially improving its bioavailability. The LS formulation passed stability tests and demonstrated stability for at least a month. This is essential for ensuring that the formulation maintains its quality and performance over time, which is a critical factor in pharmaceutical product development. Conclusion: The study suggests that the liquisolid approach in a viable alternative for improving the dissolution properties of medications that are not water-soluble.